Abante Blue Logo

About Me

Kasia Hein-Peters, MD

Scaling up Innovations

Kasia leverages human ingenuity to solve the world’s biggest health challenges. She partners with C-suite, commercial and innovation leaders in healthcare, life science, digital health and public health organizations to scale up innovations and grow organizations successfully.

Kasia graduated as a medical doctor and completed her residency in psychiatry at the Medical University in Wroclaw, Poland. After working as a clinical physician, she joined the pharmaceutical industry, driven by the passion to impact more patient lives. She oversaw the launches of several first-in-class treatments, which profoundly improved the standards of patient care, such as the first SSRI antidepressant, the first echinocandin antifungal, the first cervical cancer vaccine, and the first dengue vaccine, which profoundly changed how we practice medicine today. She introduced several other medications, vaccines, and medical devices in various therapy areas, such as infectious diseases, psychiatry, neurology, ophthalmology, urology, hematology, regenerative medicine, and immuno-oncology. She worked at Eli Lilly, Merck (MSD), Novartis, Sanofi, and Terumo BCT in specialty and hospital areas in the United States and globally.

Currently, Kasia helps her clients reach their strategic goals, achieve sustainable growth, launch leading brands, and scale up their organizations by developing innovation capabilities and applying a systematic innovation management process. She increases the odds of successfully bringing health innovations to the market, aiming to improve patient outcomes and organizations’ long-term performance.

Also, Kasia is an advisor, mentor and fractional executive at pharmaceutical, medical device and digital technology startups and accelerators.

Futuristic Innovation Management
Futuristic Innovation Management_Whole

Kasia has deep expertise in:


  • Enterprise innovation management system and innovation playbooks for all stages of innovation – ideation, selection, development, and commercialization.
  • PESTLED analyses and scenario development for strategic planning.
  • Innovation capabilities assessment and benchmarking with industry peers; identification of gaps preventing the company from meeting strategic goals.
  • Ideation sprints and hackathons.
  • InnoSurvey® evidence-based innovation capabilities assessment, based on the world’s biggest business innovation database (+5,000 companies in 105 countries).
  • The proprietary commercialization framework DIVE (Discovery – Innovation – Value – Execution) is used to develop a robust brand and enterprise strategy.
  • Got To Market Strategy development includes pre-launch, launch, and post-launch phases and cross-functional tactical plans.
  • Creating market conditions for growth through policy, advocacy, and scientific initiatives.
  • Scaling up organizations based on capabilities assessment and company development stage.